PLTR
Palantir
-- 80.550 TSLA
Tesla
-- 421.060 NVDA
NVIDIA
-- 134.700 RGTI
Rigetti Computing
-- 9.3700 AMD
Advanced Micro Devices
-- 119.210 
NEWS: Roche acquiring company for $1.5B at $9/share with CVR of $4 so up to total of $13/share ๐
Poseida Therapeutics, Inc. Announces Agreement to Be Acquired by Roche Holdings, Inc.
Poseida Therapeutics (PSTX) has announced its acquisition by Roche Holdings in a deal valued at up to $1.5 billion.
Shareholders will receive $9.00 per share in cash at closing, plus a non-tradeable contingent value right (CVR) worth up to $4.00 per share upon achieving specific milestones.
Agreement Represents a Total Equity Value of Approximately $1.0B
The acquisition will establish Roche's core capability in allogeneic cell therapy, focusing on CAR-T programs.
Agreement Includes Cell Therapy Candidates and Related Platform Technologies
Poseida will join Roche's Pharmaceuticals Division, bringing its proprietary non-viral technology platform for developing TSCM-rich CAR-T therapies.
The transaction is expected to close in Q1 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment